Total trials
3,065
Capped at 5,000
Active
193
Phase 3
662
Total enrollment
73,239,677
Pipeline matrix
Showing 40 of 228 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Elranatamab | — | 16 | |||||
| Rimegepant | — | — | 20 | ||||
| Lorlatinib | — | — | 17 | ||||
| crizotinib | — | 28 | |||||
| TIVDAK | — | — | — | — | — | 1 | |
| Binimetinib only treatment | — | — | — | — | — | 1 | |
| Encorafenib only Treatment | — | — | — | — | — | 1 | |
| Encorafenib & Binimetinib Treatment | — | — | — | — | — | 1 | |
| Treatment of Encorafenib & Binimetinib & Ribociclib | — | — | — | — | — | 1 | |
| Treatment of Encorafenib & Binimetinib & Cetuximab | — | — | — | — | — | 1 | |
| Rimegepant 75 mg ODT | — | — | — | — | — | 1 | |
| PF-08634404 | — | — | — | — | 8 | ||
| Palbociclib | — | 23 | |||||
| Etrasimod | — | — | 13 | ||||
| Fulvestrant | — | — | 11 | ||||
| Abrocitinib | — | — | — | 10 | |||
| Cetuximab | — | — | — | 9 | |||
| PF-08653944 | — | — | — | 5 | |||
| Enzalutamide | — | 20 | |||||
| 20-valent pneumococcal conjugate vaccine | — | — | 15 | ||||
| Letrozole | — | — | 14 | ||||
| Ritlecitinib | — | — | 11 | ||||
| RSVpreF | — | — | — | 8 | |||
| Chemotherapy | — | — | — | — | 7 | ||
| vepdegestrant | — | — | — | — | 7 | ||
| PF-07220060 | — | — | — | 7 | |||
| PF-07248144 | — | — | — | 5 | |||
| Oxaliplatin | — | — | — | — | 5 | ||
| PG4 | — | — | — | — | 4 | ||
| Leucovorin | — | — | — | 4 | |||
| Encorafenib | — | — | 10 | ||||
| Bevacizumab | — | — | 10 | ||||
| Pembrolizumab | — | — | 7 | ||||
| Marstacimab | — | — | — | 3 | |||
| Abemaciclib | — | — | — | 3 | |||
| Ribociclib | — | — | — | 3 | |||
| exemestane | — | — | 16 | ||||
| Irinotecan | — | — | — | 12 | |||
| VLA15 | — | — | — | — | 7 | ||
| Dexamethasone | — | — | — | 4 |
188 more active programs hidden
Next readouts
- 2020-03-20
- 2022-06-17
- 2022-10-03
- 2022-11-16
- 2023-01-31
- 2023-05-04
- 2023-07-17
- 2024-06-17
- 2024-08-26
- 2025-03-01
Top conditions
- Healthy341
- Healthy Volunteers84
- Rheumatoid Arthritis69
- Breast Neoplasms51
- Healthy Participants44
- Breast Cancer43
- Schizophrenia39
- Diabetes Mellitus, Type 236
Frequently asked questions about Pfizer
- How many clinical trials does Pfizer have on ClinicalTrials.gov?
- Pfizer is listed as the lead sponsor on 3,065 clinical trials in ClinicalTrials.gov, 193 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Pfizer's trials are in Phase 3?
- 662 of Pfizer's trials are in Phase 3, spread across 228 active drug programs.
- What therapeutic areas does Pfizer focus on?
- Pfizer's most-studied conditions on ClinicalTrials.gov are Healthy, Healthy Volunteers, Rheumatoid Arthritis, Breast Neoplasms, Healthy Participants.
- When are Pfizer's next clinical trial readouts?
- Pfizer has 10 upcoming primary-completion readouts tracked here; the soonest is “A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC”, expected around 2020-03-20.